Henagliflozein Proline Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Henagliflozein Proline Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Henagliflozein Proline can convert its Small molecule drug profile and SGLT2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Henagliflozein Proline (query alias: Henagliflozein Proline) |
|---|---|
| Modality / target | Small molecule drug; SGLT2; SGLT2 inhibitors |
| Highest global status | Approved |
| Originator | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
| Active developers | Jiangsu Hengrui Pharmaceuticals Co., Ltd., The First Affiliated Hospital of Nanchang University |
The MCP disease footprint includes Diabetes Mellitus, Type 2, disorder of aging, Chronic Kidney Diseases. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07687212 | Phase 1/2 | Not yet recruiting | 162 | Kansas City Cardiomyopathy Questionnaire (KCCQ)scale score |
| NCT07441187 | Not Applicable | Not yet recruiting | 300 | Change in HbA1c from baseline to Week 24. |
| ChiCTR2600128166 | Not disclosed | Not yet recruiting | 54 | Kansas City Cardiomyopathy Quality of Life Questionnaire Score |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Multicentre, Randomised, Controlled, Open‐Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia
Phase 3; n=210; evaluation: Positive. Reported fields: %TIR = 74.06 % ; %TIR = 79.85 %
Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study
Phase 2; n=150; evaluation: Positive. Reported fields: Telomere length(after 26 weeks): Difference (Mean) = 0.06(95.0% CI, 0.02 - 0.11), P-Value = 0.011; Telomere length(after 26 weeks): Difference (Mean) = 0.06(95.0% CI, 0.02 - 0.11), P-Value = 0.011
中国首个自研！恒瑞医药降糖复方新药恒格列净二甲双胍缓释片(I)(II)获批上市
临床3期; n=not disclosed; evaluation: 积极. Reported fields: HbA1c(vs 二甲双胍单药) = -0.80 % ; HbA1c(vs 二甲双胍单药) = -0.76 % ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Henagliflozein Proline addresses Diabetes Mellitus, Type 2, disorder of aging, Chronic Kidney Diseases. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 37 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: SGLT2 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-07-02 | Acino Pharma to commercialize Daewoong's Envlo for type 2 diabetes in eight MENA regions | Approved | US$93.3M stated total |
| 2026-06-29 | Arcera Life Sciences and Daewoong Expand Strategic Partnership to Bring Enavogliflozin to the Middle East | Approved | Financial terms not disclosed |
| 2026-03-02 | Ono Pharmaceutical Ends Forxiga Partnership with AstraZeneca in Japan | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
